All News

10 July 2007

MacroGenics IND for West Nile Virus Monoclonal Antibody is ActiveAntibodies

3 July 2007

Lexicon Develops Antibodies that Lower Triglycerides and Cholesterol as Potential New Therapy for Heart DiseaseAntibodies

3 July 2007

Ablynx announces interim results of first nanobody (R) phase i study of ALX-0081 (anti-vWF)Antibodies

2 July 2007

Genmab announces final humax-CD4 Phase II CTCL dataAntibodies

30 June 2007

WILEX to follow FDA advice and apply for a special protocol assessment (SPA) for CA9-SCANAntibodies

30 June 2007

Genmab regains rights to HuMax-CD4Antibodies

23 June 2007

Alexion’s Soliris(TM) granted marketing approval in europe for treatment of all patients with PNHAntibodies

22 June 2007

Viragen Streamlines Research Focus and Halts Further Development of OVA(TM) SystemAntibodies

20 June 2007

Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast CancerAntibodies

19 June 2007

Vegenics Licenses From CoGenesys Antibodies Against VEGF-C for Applications Including OncologyAntibodies

16 June 2007

Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia(R) (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of TherapyAntibodies

16 June 2007

GlaxoSmithKlline and Genmab present positive Phase II results with ofatumumab in patients with rheumatoid arthritis (RA)Antibodies

16 June 2007

GlaxoSmithKlline and Genmab present positive Phase II results with ofatumumab in patients with rheumatoid arthritis (RA)Antibodies

16 June 2007

Actemra: Roche’s novel rheumatoid arthritis drug shows substantial benefits for patients in OPTION studyAntibodies

15 June 2007

Genmab initiates ofatumumab frontline NHL studyAntibodies

15 June 2007

Algeta demonstrates targeted cancer-killing potential of novel alpha particle linked antibodies in leading medical journal BloodAntibodies

15 June 2007

Human Genome Sciences reports that a Phase 2 study of LymphoStat-B(R) showed significant reductions in disease activity in patients with active systemic lupus erythematosusAntibodies

15 June 2007

CIMZIA(TM) Effective in Reducing Signs and Symptoms of Rheumatoid ArthritisAntibodies

15 June 2007

Anti-TNF golimumab continues to show promise in Phase II rheumatoid arthritis studyAntibodies

14 June 2007

ENBREL Safety Data for up to Eight Years in Patients with Juvenile Rheumatoid Arthritis Being Presented at EULARAntibodies

13 June 2007

Favrille Acquires Anti-CD20 Monoclonal Antibodies from DiversaAntibodies

12 June 2007

Fractionated Radioimmunotherapy With (90)Y-epratuzumab in Non-Hodgkin’s Lymphoma Appears Safe and Active in a Phase I/II StudyAntibodies

12 June 2007

NEOPHARM, Inc. Signs Exclusive License Agreement for the Use of CINTREDEKIN BESUDOTOX (IL13-PE38QQR) for the Treatment of Pulmonary Fibrosis and AsthmaAntibodies

12 June 2007

Viventia Biotech initiates patient treatment for Phase I trial of VB6-845 anti-cancer antibodyAntibodies

9 June 2007

Regeneron submits biologics license application To US FDA for IL-1 Tap (Rilonacept) for treatment of CAPSAntibodies

8 June 2007

Abbott’s HUMIRA(R) (Adalimumab) Approved in the European Union for the Treatment of Crohn’s DiseaseAntibodies

8 June 2007

Remicade(R) Receives EU Approval as First and Only Biologic Treatment for Pediatric Crohn’s DiseaseAntibodies

7 June 2007

Abbott and Caprion Extend Partnership to Discover Antibody Targets for CancerAntibodies

7 June 2007

Actemra: New data confirms significant improvement of disease signs and symptoms in patients with rheumatoid arthritisAntibodies

6 June 2007

Phase I Results for ImClone Pipeline Anti-IGF-1R Monoclonal Antibody IMC-A12 Presented at ASCOAntibodies

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

Adalimumab (Humira) Biosimilars Pipeline Review

Report Package: TCR-Based Antibody and T-Cell Immunotherapy

CD40 Agonists & CD40/L Antagonists Pipeline Review

2020 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics

Targeted Protein Degradation by Novel PROTACs and Molecular Glues 2020: a landscape analysis of companies, technologies, targets, investors and partners from an industry perspective

Cadherin 17: A target opportunity to develop effector-enhanced drug modalities

Report Package: Bispecific Antibodies

TCR Engineered T-Cell Therapy 2018: an industry analysis of technologies, pipelines, stakeholders & deals

PD-L1 x 4-1BB (CD137) Bispecific Antibody Pipeline Review

Competitor Analysis: Complement C5 Inhibitors & C5 Receptor Antagonists